Literature DB >> 32144437

Rapid response to a single-dose rituximab combined with bortezomib in refractory and relapsed warm autoimmune hemolytic anemia.

Miao Chen1, Junling Zhuang1, Chen Yang1, Lu Zhang1, Wei Wang1, Huacong Cai1, Yanfang Yu2, Jian Li1, Daobin Zhou1, Bing Han3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32144437     DOI： 10.1007/s00277-020-03976-w

Source DB:  PubMed          Journal:  Ann Hematol        ISSN： 0939-5555            Impact factor:   3.673


× No keyword cloud information.
  1 in total

1.  Bortezomib-based antibody depletion for refractory autoimmune hematological diseases.

Authors:  Sumita Ratnasingam; Patricia A Walker; Huy Tran; Zane S Kaplan; James D McFadyen; Huyen Tran; Tse-Chieh Teh; Shaun Fleming; John V Catalano; Sanjeev D Chunilal; Anna Johnston; Stephen S Opat; Jake Shortt
Journal:  Blood Adv       Date:  2016-11-22
  1 in total
  2 in total

Review 1.  Development of New Drugs for Autoimmune Hemolytic Anemia.

Authors:  Zhengrui Xiao; Irina Murakhovskaya
Journal:  Pharmaceutics       Date:  2022-05-11       Impact factor: 6.525

2.  Combination of low-dose rituximab, bortezomib and dexamethasone for the treatment of autoimmune hemolytic anemia.

Authors:  Mingkang Yao; Jingjing Zhang; Ying Li; Linlin Lv; Lu Jia; Chunyan Yang; Yu Huang; Haihui Liu; Jian Wang; Mingtai Chen; Hao Zhang
Journal:  Medicine (Baltimore)       Date:  2022-01-28       Impact factor: 1.889
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.